The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Discovery of a Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Using a Linked-Fragment Strategy
Open accessAbstract
Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. Inhibition of PTP1B is expected to improve insulin action, and the design of small molecule PTP1B inhibitors to treat type II diabetes has received considerable attention. In this work, NMR-based screening identified a nonselective competitive inhibitor of PTP1B. A second site ligand was also identified by NMR-based screening and then linked to the catalytic site ligand by rational design. X-ray data confirmed that the inhibitor bound with the catalytic site in the native, "open" conformation. The final compound displayed excellent potency and good selectivity over many other phosphatases. The modular approach to drug design described in this work should be applicable for the design of potent and selective inhibitors of other therapeutically relevant protein tyrosine phosphatases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., Moghal, N., Lubkin, M., Kim, Y.-B., Sharpe, A. H., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5479-5489.2000 · Cited by 1,235
The T-cell protein tyrosine phosphatase
Ibarra-Sánchez, M. D. J., Simoncic, P. D., Nestel, F. R., Duplay, P., Lapp, W. S., & Tremblay, M. L. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0220 · Cited by 110
Cited by
Using chemical shift perturbation to characterise ligand binding
Williamson, M. P. (2013) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2013.02.001 · Cited by 1,460
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Self-citationAllosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Self-citationRees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
On the Value of c: Can Low Affinity Systems Be Studied by Isothermal Titration Calorimetry?
Turnbull, W. B., & Daranas, A. H. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036166s · Cited by 725
Erlanson, D. A., McDowell, R. S., & O'Brien, T. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040031v · Cited by 642
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
Zhang, S., & Zhang, Z.-Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.03.011 · Cited by 558
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Self-citationOvercoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Inhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs?
Bialy, L., & Waldmann, H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461517 · Cited by 420
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T. L., Homans, S. W., Kessler, H., Luchinat, C., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2606 · Cited by 414
PTP1B: From the sidelines to the front lines!
Tonks, N. K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00603-3 · Cited by 371
Ojida, A., Mito-oka, Y., Sada, K., & Hamachi, I. (2004) · Journal of the American Chemical Society · doi:10.1021/ja038277x · Cited by 366
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Theory and Applications of NMR-Based Screening in Pharmaceutical Research
Lepre, C. A., Moore, J. M., & Peng, J. W. (2004) · Chemical Reviews · doi:10.1021/cr030409h · Cited by 322
Combs, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901090b · Cited by 317
Ligand efficiency indices for effective drug discovery
Abad-Zapatero, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.469 · Cited by 279
Self-citationProtein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development
Barr, A. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.241 · Cited by 266
Hit discovery and hit-to-lead approaches
Keserű, G. M., & Makara, G. M. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.016 · Cited by 256
Cellular chromium enhances activation of insulin receptor kinase
Wang, H., Kruszewski, A., & Brautigan, D. L. (2005) · Biochemistry · doi:10.1021/bi0473152 · Cited by 121
Metadata
- Authors
- Szczepankiewicz, B. G., Liu, G., Hajduk, P. J., Abad-Zapatero, C., Pei, Z., Xin, Z., Lubben, T. H., Trevillyan, J. M., Stashko, M. A., Ballaron, S. J., Liang, H., Huang, F., Hutchins, C. W., Fesik, S. W., & Jirousek, M. R.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-03-12
- Volume
- 125
- Issue
- 14
- Pages
- 4087-4096
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2134486592
- Cited by
- 231
- References
- 3
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.